Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other Non-Current Assets (2021 - 2025)

Inmune Bio's Other Non-Current Assets history spans 5 years, with the latest figure at $746000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 809.76% year-over-year to $746000.0; the TTM value through Sep 2025 reached $746000.0, up 809.76%, while the annual FY2024 figure was $79000.0, 39.69% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $746000.0 at Inmune Bio, up from $570000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $746000.0 in Q3 2025 and bottomed at $49000.0 in Q1 2025.
  • The 5-year median for Other Non-Current Assets is $99000.0 (2021), against an average of $164470.6.
  • The largest YoY upside for Other Non-Current Assets was 809.76% in 2025 against a maximum downside of 53.77% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $99000.0 in 2021, then changed by 0.0% to $99000.0 in 2022, then soared by 32.32% to $131000.0 in 2023, then plummeted by 39.69% to $79000.0 in 2024, then surged by 844.3% to $746000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Other Non-Current Assets are $746000.0 (Q3 2025), $570000.0 (Q2 2025), and $49000.0 (Q1 2025).